Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity

Marylyn D. Ritchie, David W. Haas, Alison A. Motsinger, John P. Donahue, Huso Erdem, Stephen Raffanti, Peter Rebeiro, Alfred L. George, Richard B. Kim, Jonathan L. Haines, Timothy R. Sterling

Research output: Contribution to journalArticlepeer-review

84 Scopus citations

Abstract

This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenzor nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001).

Original languageEnglish (US)
Pages (from-to)779-782
Number of pages4
JournalClinical Infectious Diseases
Volume43
Issue number6
DOIs
StatePublished - Sep 15 2006

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity'. Together they form a unique fingerprint.

Cite this